DEENOVA
11.7.2022 06:02:14 CEST | Business Wire | Press release
Following its previous announcements in March 2022, for the release of three new innovative additions to its award winning D3 product line of mechatronic solutions, Deenova further consolidates its technological leadership in the field of pharmacy automation, and announced today the unveiling of the second generation of its ALL-IN-1 robot, able to automatically repack in unit dose, all medication forms: oral solids and liquids such as ampoules, syringes, vials and all types of patches sachet and suppositories.
The ultimate generation of this innovative fully automated repackaging robot has been designed to ensure the efficiency and unmatched fluency of its predecessor, while improving versatility and reliability with optimized movements of the robotic arm.
With the operator in mind, and for an unrivaled customer experience, particular attention has been put in the functional aspects of the technology such as improving the vision system with new AI functionalities, lowering the overall noise level, improving the ergonomics and developing a smooth and intuitive user interface, perfectly in line with Deenova ’s vision of “sensitive robotics ”: a technology in contact with the human side in a reliable support relationship anytime, anywhere.
Fulvio Rudello , Chief Operation Officer at Deenova , declared: “I am very excited to see that our new ALL-IN-1 robot has successfully passed all the factory validation tests, and is now fully operational in Deenova ’s central unit dose laboratory near Piacenza, serving 22 hospitals sites in Italy, with more than 6 millions unit doses produced per year. This is the first step of a wider upgrading process of our facility and will be followed by the gradual replacement of existing equipment starting with implementation during the first quarter of 2023, of the new D3 AIDE Cut , Deenova 's latest modular mechatronic solutions for the repackaging of oral solid medications in unit doses.”
“Our 100% customer retention rate in Italy, after more that 15 years of operations” explained Christophe Jaffuel , Chief Commercial Officer at Deenova “motivates us to relentlessly define new standards of performance and customer experience. Having this new ALL-IN-1 robot, fully operating in our facilities is a great premise for our upcoming breakthrough installations in UK and Germany”
Since 2004, Deenova is the undisputed leading supplier of mechatronics solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry. Deenova ’s unique, patented and fully integrated solutions ease the healthcare providers’ growing pressures to improve patient safety, reduce therapy errors, minimize waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.
Please visit www.deenova.com for additional information on its market leading solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220710005007/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Third-Party EPDs Confirm C-Crete Cement Cuts Embodied Carbon by up to 95% — and It’s Already Being Poured Commercially28.7.2026 14:05:00 CEST | Press release
Two independently verified Environmental Product Declarations confirm cradle-to-gate carbon as low as 43.1 kg CO2-eq per metric ton. C-Crete’s platform technology turns a wide range of local rocks and industrial by-products into clinker-free cementitious binder — already in commercial use and adaptable to cement standards worldwide. C-Crete Technologies has published two Environmental Product Declarations (EPDs) verifying that its cements cut embodied carbon by up to 95% versus conventional portland cement. C-Crete’s technology converts a broad range of natural rocks and industrial by-products into cementitious binders with no clinker and no kiln, so production is inherently decentralized — and it is already being poured in commercial concrete today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728132467/en/ Representative C-Crete's project portfolio. More than 4000 tons of C-Crete's ultra-low carbon concrete have been
ExaGrid Releases Version 8.128.7.2026 14:00:00 CEST | Press release
Latest update includes support of Cohesity DataProtect, share quotas for MSPs, and NFS encryption over the wire ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the most comprehensive security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced the release of ExaGrid software version 8.1. The latest version includes: Support for Cohesity DataProtect Uses S3 protocol. Supports Cohesity Cloud Archive Direct. ExaGrid further deduplicates Cohesity deduplicated data, cutting the storage footprint in half. ExaGrid works with Cohesity NetBackup for mixed NetBackup and DataProtect environments. NFS encrypted over the wire Available for backup apps that support NFS encryption over the wire. ExaGrid already supports encryption over the wire with other protocols such as the Veeam Data Mover, CIFS, and S3. Share Quota ExaGrid already tracks how much data is going into each share. Now, a Managed Service Provider (MSP) can s
Omilia Appoints David Ogden as VP of Revenue Operations28.7.2026 14:00:00 CEST | Press release
Enterprise SaaS revenue operations leader joins Omilia to build the operational backbone for its next phase of global growth Omilia, a global leader in Self-Learning Agentic CX, today announced the appointment of Dave Ogden as Vice President of Revenue Operations. Ogden will be responsible for scaling Omilia’s global revenue operations function spanning sales operations, forecasting, and commercial execution as the company accelerates growth across its key markets. In this role, Ogden will design and operate the revenue infrastructure that connects sales, marketing, and customer success, including forecasting, pipeline management, and deal desk operations. He joins as Omilia expands its direct and partner-led go-to-market across the US, Europe, Latin America and Australia, and will play a central role in ensuring that growth scales in a disciplined, data-driven way. Ogden brings more than 15 years of enterprise SaaS revenue and commercial operations experience. He spent nine years at F
Nine in 10 LPs More Likely to Commit to Funds Using Leverage When Disclosure is Clear28.7.2026 14:00:00 CEST | Press release
90% of LPs say adequate disclosure around fund-level leverage and liquidity tools would increase their likelihood to commit or re-upGPs use 2.4 liquidity tools on average as fund-level financing becomes embedded in private capital63% of GPs cite facility-data integration with accounting and investor reporting as a major operational challenge Fund-level leverage and liquidity tools have moved from specialist financing techniques to mainstream private capital infrastructure, according to new research from CSC, the leading provider of global business administration and compliance solutions. The findings show that limited partners (LPs) are increasingly open to the use of these tools when disclosure is clear, but general partners (GPs) face growing pressure to prove that the operating model behind them is controlled, transparent, and investor-ready. CSC¹ surveyed 300 GPs and 200 LPs across North America, Europe, the U.K., and Asia Pacific. The report, Future Private Capital CFO 2026: How C
B-Secur and CSEM Partner to Bring Clinically-Validated Heart Monitoring to Health Wearables28.7.2026 14:00:00 CEST | Press release
CSEM, the Swiss-based technology innovation centre, and B-Secur, a leader in advanced biosensing technology, today announced a partnership to bring clinically-validated heart monitoring capability to health wearables. The collaboration pairs CSEM's 25+ years of leadership in PPG-based vital signs monitoring with B-Secur's multiple FDA-cleared ECG algorithms and analytics, offering device manufacturers and digital health companies a route to integrating more accurate, market-ready heart monitoring into their products — for applications including remote patient monitoring, cardiovascular health, and chronic disease management. “By combining CSEM’s expertise in photoplethysmography-based vital signs monitoring with B-Secur’s ECG analytics, we are enabling a new class of multimodal sensing solutions that deliver clinically relevant insights. This partnership reflects our commitment to translating cutting-edge sensing and algorithm technologies into real-world healthcare applications.” Jose
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom